uniQure (QURE) Stock Price, News & Analysis

Company Overview

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Key Stats

• Today's Range: $15.72 to $16.66
• 50-Day Range: $13.28 to $16.90
• 52-Week Range: $4.45 to $19.18
• Volume: 1.36 million shs
• Average Volume: 1.27 million shs
• Market Capitalization: $887.80 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $37.45
• Consensus Rating: Buy

uniQure Stock Analysis - MarketRank™

uniQure scored higher than 56% of companies evaluated by MarketBeat, and ranked 498th out of 935 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

uniQure has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, 2 hold ratings, and no sell ratings.

Amount of Analyst Coverage

uniQure has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for uniQure are expected to grow in the coming year, from ($3.75) to ($3.10) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of uniQure is -4.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of uniQure is -4.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

17.99% of the float of uniQure has been sold short.

Short Interest Ratio / Days to Cover

uniQure has a short interest ratio ("days to cover") of 7.1.

Change versus previous month

Short interest in uniQure has recently increased by 8.80%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

uniQure does not currently pay a dividend.

Dividend Growth

uniQure does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

17.99% of the float of uniQure has been sold short.

Short Interest Ratio / Days to Cover

uniQure has a short interest ratio ("days to cover") of 7.1.

Change versus previous month

Short interest in uniQure has recently increased by 8.80%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.9 / 5
• News Sentiment: 1.94

News Sentiment

uniQure has a news sentiment score of 1.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.65 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for uniQure this week, compared to 0 articles on an average week.

Search Interest

7 people have searched for QURE on MarketBeat in the last 30 days. This is an increase of 600% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added uniQure to their MarketBeat watchlist in the last 30 days. This is a decrease of -83% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, uniQure insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $322,426.00 in company stock.

Percentage Held by Insiders

Only 4.79% of the stock of uniQure is held by insiders.

Percentage Held by Institutions

78.83% of the stock of uniQure is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

QURE Stock Analysis - Frequently Asked Questions

How have QURE shares performed this year?

uniQure's stock was trading at $17.66 at the beginning of the year. Since then, QURE shares have decreased by 8.4% and is now trading at $16.18.

How were uniQure's earnings last quarter?

uniQure N.V. (NASDAQ:QURE) released its quarterly earnings results on Tuesday, July, 29th. The biotechnology company reported ($0.69) EPS for the quarter, beating the consensus estimate of ($0.89) by $0.20. The biotechnology company earned $5.26 million during the quarter, compared to analyst estimates of $5 million. uniQure had a negative trailing twelve-month return on equity of 1,010.74% and a negative net margin of 1,387.98%.
Read the conference call transcript.

Who are uniQure's major shareholders?

Top institutional shareholders of uniQure include Vestal Point Capital LP (6.74%), Aberdeen Group plc (5.02%), Jefferies Financial Group Inc. (3.82%) and Nantahala Capital Management LLC (3.74%). Insiders that own company stock include Matthew C Kapusta, Christian Klemt, Ricardo Dolmetsch, Walid Abi-Saab, Jeannette Potts, Alexander Edward Kuta III, Pierre Caloz, Robert Gut, Madhavan Balachandran, Jeremy P Springhorn, David D Meek, Leonard E Post, Rachelle Suzanne Jacques, Jack Kaye and Paula Soteropoulos.
View institutional ownership trends.

How do I buy shares of uniQure?

Shares of QURE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of uniQure own?

Based on aggregate information from My MarketBeat watchlists, some other companies that uniQure investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), CrowdStrike (CRWD), Advanced Micro Devices (AMD), Arista Networks (ANET) and ServiceNow (NOW).

Company Calendar

• Last Earnings: 7/29/2025
• Today: 8/17/2025
• Next Earnings (Estimated): 11/04/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:QURE
• CIK: 1590560
• Web: www.uniqure.com
• Phone: (120) 240-6000
• Fax: 31-20-566-9272
• Employees: 500
• Year Founded: N/A

Price Target and Rating

• Average Price Target for uniQure: $37.45
• High Price Target: $70.00
• Low Price Target: $20.00
• Potential Upside/Downside: +131.5%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 11 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.92)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$239.56 million
• Net Margins: -1,387.98%
• Pretax Margin: -1,375.80%
• Return on Equity: -1,010.74%
• Return on Assets: -33.27%

Debt

• Debt-to-Equity Ratio: 1.53
• Current Ratio: 9.98
• Quick Ratio: 9.98

Sales & Book Value

• Annual Sales: $27.12 million
• Price / Sales: 32.74
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.07) per share
• Price / Book: -231.14

Miscellaneous

• Outstanding Shares: 54,870,000
• Free Float: 52,239,000
• Market Cap: $887.80 million
• Optionable: Optionable
• Beta: 0.11